Apexigen- Warrants (29/07/2027) EBIT

The latest EBIT for APGNW is $-28M as of June 2023. That compares with $-1.8B in the prior-year period — up 98.5% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Apexigen- Warrants (29/07/2027)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, APGNW's EBIT moved from $-1.8B to $-28M — a 98.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Apexigen- Warrants (29/07/2027)'s operating scale or balance-sheet position.

Against its sector companies, APGNW currently prints $-28M for EBIT, while the sector average sits near $-63M. That is roughly 55.5% above the sector mean. Large gaps often invite a closer look at Apexigen- Warrants (29/07/2027)'s growth, margins, and balance sheet.

A EBIT figure of $-28M for APGNW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting APGNW's EBIT ($-28M), review year-over-year change from $-1.8B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.